Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026

As of Nov. 2, 2026, the Russell 2000 was up 13.3% year to date, ahead of the S&P 500 (+10.2%) and Dow (+8.2%), helped by domestic-focused companies and favorable U.S. policies. The article cautions that this outperformance may not persist: the Russell 2000 ETF returned 144% over 10 years versus 187% for the Dow and 260% for the S&P 500, and about 32% of Russell companies have floating-rate debt versus 6% of S&P 500 companies, making them more exposed to further rate increases.

Analysis

The more important signal is the change in factor leadership, not the small-cap index’s headline outperformance. If the rally broadens into earnings upgrades, domestic cyclicals may keep attracting flows; if it is mainly policy optimism and multiple expansion, higher discount rates and refinancing costs can reverse it quickly. Domestic revenue is not equivalent to insulation: tariffs may support some U.S. producers while raising input costs for companies reliant on imported components, and weaker global exposure can also mean less diversified demand.

The index’s breadth cuts both ways. A handful of spectacular constituent gains have little direct weight in the ETF, so they do not establish broad underlying earnings acceleration. Conversely, the small-cap exposure to floating-rate borrowing makes a renewed tightening cycle an asymmetric risk: interest expense can pressure cash flow before slower-moving policy benefits show up. The tax and deregulation tailwind is conditional on implementation and companies having profitable investment opportunities; it should not be treated as an immediate earnings uplift across the index.

Near term, momentum and domestic-policy positioning can sustain relative strength. Over 1–3 months, Fed guidance, Treasury yields, and breadth of earnings revisions matter more than the policy narrative. Over 6–18 months, sustained outperformance requires cash-flow growth to offset financing costs. A dovish pivot or broad small-cap earnings upgrades would invalidate the bearish relative-value case; a higher-yield repricing alongside weakening revisions would strengthen it.

Key Decisions for Investors

• Avoid chasing VTWO solely on recent relative performance. Consider a modest, hedged short VTWO / long SPY position only if the relative trend rolls over while Treasury yields remain firm; this targets the financing-sensitivity gap rather than an outright market decline. Risk: a dovish Fed, falling yields, or improving small-cap earnings breadth could drive further catch-up.
• Use Fed communications, Treasury yields, and small-cap earnings-revision breadth as 1–3 month triggers. Falsify the relative underweight if yields fall materially and revisions broaden across Russell constituents; strengthen it if financing pressure rises and revisions deteriorate.
• Do not infer ETF-wide fundamentals from the outsized moves in Twist Bioscience (TWST) or 10x Genomics (TXG): their reported portfolio weights are small. Treat those names as separate, high-volatility company exposures and verify valuation, bookings, and cash-flow trends before making a stock-specific trade.
• Monitor tariff implementation and company disclosures on imported input costs, floating-rate debt, and refinancing schedules. The article does not establish which constituents benefit net of costs; absent that evidence, treat the policy tailwind as a watch item rather than a broad index earnings forecast.